OTO-313

DRUG2 trials

Sponsors

Otonomy, Inc.

Conditions

Subjective TinnitusTinnitus, Subjective

Phase 1

OTO-313 in Subjects With Subjective Tinnitus

CompletedNCT03918109

Otonomy, Inc.Tinnitus, Subjective

Start: 2019-04-04End: 2020-05-29Updated: 2022-12-23

Phase 2

OTO-313 in Subjects With Unilateral Subjective Tinnitus

CompletedNCT04829214

Otonomy, Inc.Subjective Tinnitus

Start: 2021-03-22End: 2022-06-30Updated: 2023-01-06